Vera Therapeutics, Inc. financial data

Symbol
VERA on Nasdaq
Industry
Pharmaceutical Preparations
Location
2000 Sierra Point Parkway, Suite 1200, Brisbane, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.15K % +184%
Debt-to-equity 19 % -57.3%
Return On Equity -39.3 % +46.4%
Return On Assets -33.1 % +34.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63.3M shares +42.5%
Entity Public Float 1.7B USD +278%
Common Stock, Value, Issued 64K USD +45.5%
Weighted Average Number of Shares Outstanding, Basic 55.3M shares +29.5%
Weighted Average Number of Shares Outstanding, Diluted 55.3M shares +29.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 126M USD +61.3%
General and Administrative Expense 41M USD +72.4%
Operating Income (Loss) -167M USD -63.9%
Nonoperating Income (Expense) 15M USD +149%
Net Income (Loss) Attributable to Parent -152M USD -58.5%
Earnings Per Share, Basic -2.75 USD/shares -22.2%
Earnings Per Share, Diluted -2.75 USD/shares -22.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 92.6M USD +103%
Marketable Securities, Current 548M USD +377%
Other Assets, Current 913K USD -59.2%
Assets, Current 651M USD +279%
Property, Plant and Equipment, Net 960K USD +943%
Operating Lease, Right-of-Use Asset 3.37M USD +14.3%
Assets 656M USD +274%
Accounts Payable, Current 7.67M USD -31.1%
Employee-related Liabilities, Current 6.82M USD +73.5%
Accrued Liabilities, Current 16.2M USD +85.4%
Liabilities, Current 25.4M USD +13.8%
Operating Lease, Liability, Noncurrent 2.47M USD +76.9%
Liabilities 78.5M USD +6.32%
Accumulated Other Comprehensive Income (Loss), Net of Tax 393K USD +56.6%
Retained Earnings (Accumulated Deficit) -461M USD -49.2%
Stockholders' Equity Attributable to Parent 577M USD +468%
Liabilities and Equity 656M USD +274%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -33.8M USD -28.7%
Net Cash Provided by (Used in) Financing Activities 277M USD +156%
Net Cash Provided by (Used in) Investing Activities -219M USD -1892%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.4M USD -75.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 92.6M USD +103%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.52M USD -53.3%
Deferred Tax Assets, Valuation Allowance 107M USD +49.7%
Deferred Tax Assets, Gross 108M USD +49.3%
Operating Lease, Liability 3.95M USD +3.13%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 5.34M USD +8.89%
Operating Lease, Liability, Current 1.48M USD -39.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 830K USD -55.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.29M USD -24.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +22%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.39M USD +29.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 966K USD
Deferred Tax Assets, Operating Loss Carryforwards 38.7M USD +40.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.05M USD +35.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 995K USD
Operating Lease, Payments 764K USD +2.41%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 792K USD +10.2%
Share-based Payment Arrangement, Expense 20.8M USD +81%
Interest Expense 5.82M USD +130%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%